Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy

References

• Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Garuti F, Neri A, Avanzato F, Gramenzi A. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021;41:585–597. doi:10.1111/liv.14735
   PubMed Web of Science ®Google Scholar
• Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410–420. doi:10.1001/jamasurg.2022.7989
   PubMed Web of Science ®Google Scholar
• Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022;11:592–596. doi:10.21037/hbsn-22-143
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133–1146. doi:10.1016/S0140-6736(23)00961-3
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12:28–51. doi:10.1016/j.prro.2021.09.004
   PubMed Web of Science ®Google Scholar
• Sharma D, Thaper D, Kamal R, Yadav HP. Role of palliative SBRT in Barcelona clinic liver cancer-stage C hepatocellular carcinoma patients. Strahlenther Onkol. 2023;199:838–846. doi:10.1007/s00066-023-02065-x
   PubMed Web of Science ®Google Scholar
• Lewis S, Dawson L, Barry A, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Rep. 2022;4:100498. doi:10.1016/j.jhepr.2022.100498
   PubMedGoogle Scholar
• Nguyen QN, Chun SG, Chow E, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5:872–878. doi:10.1001/jamaoncol.2019.0192
   PubMed Web of Science ®Google Scholar
• Dawson L, Winter K, Knox J, et al. NRG/RTOG 1112: randomized Phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). J Clin oncol. 2023;41:489. doi:10.1200/JCO.2023.41.4_suppl.489
   Web of Science ®Google Scholar
• Chen YX, Yang P, Du SS, et al. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a Phase II clinical trial. World J Gastroenterol. 2023;29:3871–3882. doi:10.3748/wjg.v29.i24.3871
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Patin EC, Pedersen M, Wilkins A. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20:203–217. doi:10.1038/s41568-020-0246-1
   PubMed Web of Science ®Google Scholar
• Qiu X, Shi Z, Tong F, et al. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Hum Vaccin Immunother. 2023;19:2178791. doi:10.1080/21645515.2023.2178791
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada K, Bagnato VS, Romero MP. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci. 2021;23:22. doi:10.3390/ijms23010022
   PubMedGoogle Scholar
• Erler D, Brotherston D, Sahgal A, et al. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. Radiother Oncol. 2018;127:304–309. doi:10.1016/j.radonc.2018.03.030
   PubMed Web of Science ®Google Scholar
• Oldenburger E, Brown S, Willmann J, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol. 2022;173:240–253. doi:10.1016/j.radonc.2022.06.002
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9:1651–1659. doi:10.1001/jamaoncol.2023.4003
   PubMed Web of Science ®Google Scholar
• Stefanini B, Ielasi L, Chen R. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23:279–291. doi:10.1080/14737140.2023.2181162
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400:1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Sapir E, Tao Y, Schipper MJ, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122–130. doi:10.1016/j.ijrobp.2017.09.001
   PubMed Web of Science ®Google Scholar
• Shen PC, Chang WC, Lo CH, et al. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2019;105:307–318. doi:10.1016/j.ijrobp.2019.05.066
   PubMed Web of Science ®Google Scholar
• Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:169–178. doi:10.1016/S2468-1253(22)00339-9
   PubMed Web of Science ®Google Scholar
• Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73:121–129. doi:10.1016/j.jhep.2020.03.005
   PubMed Web of Science ®Google Scholar
• Kimura T, Takeda A, Sanuki N, et al. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatol Res. 2021;51:461–471. doi:10.1111/hepr.13595
   PubMed Web of Science ®Google Scholar
• Shen J, Yan J, Zhu S, et al. The efficacy and safety of hypofractionated radiation therapy with tomotherapy for advanced or recurrent hepatocellular carcinoma. Front Oncol. 2021;11:559112. doi:10.3389/fonc.2021.559112
   PubMed Web of Science ®Google Scholar
• D’Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76:1185–1198. doi:10.1016/j.jhep.2021.11.013
   PubMed Web of Science ®Google Scholar
• Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551:340–345. doi:10.1038/nature24302
   PubMed Web of Science ®Google Scholar
• Ishtiaq SM, Arshad MI, Khan JA. PPARγ signaling in hepatocarcinogenesis: mechanistic insights for cellular reprogramming and therapeutic implications. Pharmacol Ther. 2022;240:108298. doi:10.1016/j.pharmthera.2022.108298
   PubMed Web of Science ®Google Scholar
• Valero C, Lee M, Hoen D, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12:729. doi:10.1038/s41467-021-20935-9
   PubMed Web of Science ®Google Scholar
• Chan SL, Wong LL, Chan KA, et al. Development of a novel inflammation-based index for hepatocellular carcinoma. Liver Cancer. 2020;9:167–181. doi:10.1159/000504252
   PubMed Web of Science ®Google Scholar
• Lo CH, Lee HL, Hsiang CW, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts survival and liver toxicity in patients with hepatocellular carcinoma treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2021;109:474–484. doi:10.1016/j.ijrobp.2020.09.001
   PubMed Web of Science ®Google Scholar
• Ruan GT, Xie HL, Zhang HY, et al. Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer. Clin Nutr. 2022;41:2284–2294. doi:10.1016/j.clnu.2022.08.025
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Saito H, Fukumoto Y, et al. The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment. Surg Today. 2023;53:940–948. doi:10.1007/s00595-022-02638-w
   PubMed Web of Science ®Google Scholar
• Utsumi M, Inagaki M. Preoperative lymphocyte-to-C-reactive protein ratio predicts hepatocellular carcinoma recurrence after surgery. Ann Surg Treat Res. 2022;103:72–80. doi:10.4174/astr.2022.103.2.72
   PubMed Web of Science ®Google Scholar
• Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology. 2020;71:907–916. doi:10.1002/hep.30858
   PubMed Web of Science ®Google Scholar
• He H, Chen S, Fan Z, et al. Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma. Cell Discov. 2023;9:60. doi:10.1038/s41421-023-00563-x
   PubMed Web of Science ®Google Scholar
• Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734–5742. doi:10.1200/JCO.2009.23.1282
   PubMed Web of Science ®Google Scholar